Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates

NEXT STORY
Cooper University Health Care Announces Expansion of Extensive Military Training Programs with Partnership to Provide Specialized Medical Training to U.S. Military Personnel as Part of SMART Program
PREV STORY
Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Recce Pharmaceuticals to Give Opening R&D Address at World Anti-Microbial Resistance Congress 2021

author_avatar
NASDAQ Market News

Asia-Pacific Hand Sanitizer Market to 2026 by Product (Gel, Foam, Spray, Other), Distribution Channel (Offline and Online), & End-User (Hospitals , Hotels, Households and Others)

author_avatar
NASDAQ Market News

Fluidigm Introduces Single-Cell TCR Sequencing on the C1 System at Immunology 2016™

SOUTH SAN FRANCISCO, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today ...

author_avatar
NASDAQ Market News